

CANCER IN IDAHO – 2007 Preliminary

December 2008

**A Publication of the
Cancer Data Registry of Idaho**



Editors:

Christopher J. Johnson, MPH, Epidemiologist
Stacey L. Carson, RHIT, CTR, Vice President Operations and Registry Services

Contributors:

Denise Jozwik, RHIT, CTR, Director
Maryann Sacks, RHIT, CTR, Cancer Data Controller
Loretta E. Travers, RHIT, CTR, Cancer Data Controller

CANCER DATA REGISTRY OF IDAHO
P.O. Box 1278
Boise, Idaho 83701-1278
208-338-5100 ext 213 (phone)
208-344-0180 (FAX)
<http://www.idcancer.org>



IDAHO DEPARTMENT OF
HEALTH & WELFARE

PREFACE

"*Cancer in Idaho - 2007*," the thirty-first annual report of the Cancer Data Registry of Idaho (CDRI), contains data on cancer cases diagnosed during 2007 among Idaho residents. These data can be used by public health officials, hospital administrators, physicians, the Comprehensive Cancer Alliance for Idaho and others to effectively plan services, prioritize health resource allocations, develop and measure prevention and intervention strategies, and identify high risk populations within the state of Idaho.

ACKNOWLEDGMENTS

The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare, Division of Health, to provide a statewide cancer surveillance system.

The statewide cancer registry database is a product of collaboration among many report sources including: hospitals, physicians, surgery centers, pathology laboratories, and other states in which Idaho residents are diagnosed and/or treated for cancer. Their cooperation in reporting timely, accurate, and complete cancer data is acknowledged and sincerely appreciated.

CDRI would also like to thank the Division of Health, Idaho Department of Health and Welfare, and the Comprehensive Cancer Alliance for Idaho for their continued partnership and for using CDRI data as a tool in cancer control and prevention.

We acknowledge the Centers for Disease Control and Prevention, for its support of CDRI, and the printing and distribution of *Cancer in Idaho - 2007* under cooperative agreement 5U58DP000767-02 awarded to CDRI. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

SUGGESTED CITATION:

Johnson CJ, Carson SL. *Cancer in Idaho, 2007, Preliminary Data*. Boise, ID: Cancer Data Registry of Idaho; December 2008.

COPYRIGHT INFORMATION:

All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

Introduction to the Cancer Data Registry of Idaho (CDRI)

Purpose of the Registry

Population-based cancer registries are essential for assessing the extent of cancer burden in a specified geographic area. The Cancer Data Registry of Idaho (CDRI) is a population-based cancer registry that collects incidence and survival data on all cancer patients who reside in the state of Idaho or who are diagnosed and/or treated for cancer in the state of Idaho. The goals of the CDRI are to:

- ◆ determine the incidence of cancer in the state of Idaho with respect to geographic, demographic, and social characteristics;
- ◆ monitor trends and patterns of cancer incidence over time;
- ◆ identify high risk populations;
- ◆ provide a database and serve as a resource in conducting epidemiologic studies; and
- ◆ provide data to assist public health officials, hospital administrators, and physicians to effectively plan services, prioritize health resource allocations and develop and measure prevention and intervention strategies.

History and Funding of the Registry

CDRI was established in 1969 and became population-based in 1971. The Idaho State Legislature has provided guidelines for the establishment, requirements, and funding of the statewide cancer registry. The operations of the registry are mandated by Idaho Code 57-1703 through 57-1707. Funding is appropriated in Idaho Code 57-1701 and 63-2520, which delineates a portion (less than one percent) of the cigarette tax to be dedicated to fund the statewide cancer registry. Through the National Program of Cancer Registries (NPCR), additional funding has been awarded to CDRI from the Centers for Disease Control and Prevention (CDC) to

enhance timely, complete and accurate data collection, computerization, and reporting of reliable data.

Collection of Data

Each Idaho hospital, outpatient surgery center, and pathology laboratory is responsible for the complete ascertainment of all data on cancer diagnoses and treatments provided in its facility within six months of diagnosis. Sources for identifying eligible cases include:

- ◆ hospitals,
- ◆ outpatient surgery centers,
- ◆ private pathology laboratories,
- ◆ free-standing radiation centers,
- ◆ physicians (for patients not receiving cancer diagnoses and/or treatment in the above sources),
- ◆ death certificates, and
- ◆ other state cancer registries reporting an Idaho resident with cancer (as negotiated).

Incomplete case reporting by US Veterans Affairs (VA) hospitals since late 2004 may have resulted in 40,000 to 70,000 cases being missed nationwide each year.¹⁹ The impact of incomplete case reporting of VA cases on Idaho cancer statistics is unknown, but acknowledged.

When a cancer case is reported from more than one source, the information is consolidated into one record.

Reported cases contain the following data:

- ◆ patient demographics (including geographic place of residence at time of cancer diagnosis);
- ◆ description of cancer (including date of diagnosis, primary site, metastatic sites, histology, extent of disease, etc.);

- ◆ first course treatment; and
- ◆ follow-up data for purposes of calculating survival rates.

Primary site, behavior, grade, and histology were coded according to the *International Classification of Diseases for Oncology, 3rd edition*.¹ Stage of disease variables were coded using SEER's *Summary Staging Manual 2000*, the *AJCC Manual for Staging of Cancer, 6th edition*, and the *Collaborative Staging Manual, Version 1.04*.^{2,3,16} SEER Summary Stage was coded using the SEER manual, not derived from Collaborative Staging variables. All other variables were coded following the rules of the North American Association of Central Cancer Registries (NAACCR), the National Cancer Institute's SEER program, and the American College of Surgeons Commission on Cancer.⁴⁻⁶ Beginning with cases diagnosed in 2007, new rules for coding multiple primaries and histologies were applied.²⁰ These rules standardize the process of determining the number of primary cases and provide guidance for identifying histologic lineages.

Reportable Cases

All in-situ or malignant neoplasms are reportable to CDRI. The database includes all cases of carcinoma, sarcoma, melanoma, lymphoma, and leukemia, diagnosed by histology/cytology, radiology, laboratory testing, clinical observation, and autopsy.

Also reportable are benign tumors of the brain, meninges, pineal gland, and pituitary gland.

Basal and squamous cell carcinomas of the skin are excluded except when occurring on a mucous membrane or if the AJCC stage group is II, III, or IV.

Under Idaho Code and as recommended by NAACCR, cervix in-situ cases are not currently reportable.

Confidentiality of Data

Idaho state law ensures the protection of confidential data and restricts the release of identifying data. Only aggregate data are published. The same law protects report sources from any liability for reporting confidential data to CDRI. Persons with access to confidential data are required to sign a pledge of confidentiality and are subject to penalty if they, through negligence or willful misconduct, disclose confidential data.

Quality Assurance

To assure validity and reliability of data presented, CDRI has many mechanisms in place to check data for quality and completeness. CDRI uses EDITS software which has standard edits using algorithms that check the content of data fields against an encoded set of acceptable possible contents and flags the acceptability of coded data. Edits include field edits, inter-field edits, and inter-record edits. Edits check for unlikely sex/site, site/histology and site/age combinations. In addition to computerized edits, each case is manually reviewed for errors.

Records are also routinely checked for duplicate entries. Duplicate case checking is performed both manually and electronically using several methodologies.

CDRI has met NPCR program standards and is recognized as a "gold standard registry" for quality, completeness and timeliness as designated by NAACCR. These designations enable Idaho data to be included in *United States Cancer Statistics* and all NAACCR volumes of *"Cancer Incidence in North America."*

2007 Idaho Cancer Incidence Rates by Sex (Preliminary)

Primary Site	Total			Male			Female		
	Rate	Cases	Pop	Rate	Cases	Pop	Rate	Cases	Pop
All Sites	460.4	6,781	1,499,402	520.5	3,587	754,499	413.7	3,194	744,903
Bladder	20.5	296	1,499,402	34.8	229	754,499	8.3	67	744,903
Brain - malignant	6.7	99	1,499,402	6.9	52	754,499	6.4	47	744,903
Brain and other CNS - non-malignant	8.2	120	1,499,402	5.0	35	754,499	11.0	85	744,903
Breast	64.4	958	1,499,402	1.0	7	754,499	123.3	951	744,903
Breast - in situ	11.7	175	1,499,402	0.2	2	754,499	22.6	173	744,903
Cervix	2.4	35	1,499,402	0.0	0	754,499	4.7	35	744,903
Colorectal	40.4	588	1,499,402	44.9	303	754,499	36.5	285	744,903
Corpus Uteri	11.9	180	1,499,402	0.0	0	754,499	23.0	180	744,903
Esophagus	4.6	69	1,499,402	8.2	58	754,499	1.4	11	744,903
Hodgkin Lymphoma	2.6	38	1,499,402	2.6	20	754,499	2.5	18	744,903
Kidney and Renal Pelvis	14.1	208	1,499,402	17.3	122	754,499	11.2	86	744,903
Larynx	2.9	43	1,499,402	4.6	33	754,499	1.3	10	744,903
Leukemia	13.9	205	1,499,402	16.5	113	754,499	11.9	92	744,903
Liver and Bile Duct	3.9	57	1,499,402	4.9	35	754,499	2.8	22	744,903
Lung and Bronchus	55.7	809	1,499,402	66.0	438	754,499	47.8	371	744,903
Melanoma of the Skin	22.7	334	1,499,402	27.1	191	754,499	19.1	143	744,903
Myeloma	5.6	82	1,499,402	7.6	51	754,499	4.0	31	744,903
Non-Hodgkin Lymphoma	20.1	297	1,499,402	24.2	166	754,499	16.7	131	744,903
Oral Cavity and Pharynx	10.9	164	1,499,402	15.8	115	754,499	6.3	49	744,903
Ovary	7.6	116	1,499,402	0.0	0	754,499	14.6	116	744,903
Pancreas	11.4	168	1,499,402	13.2	91	754,499	9.6	77	744,903
Prostate	77.4	1150	1,499,402	164.7	1150	754,499	0.0	0	744,903
Stomach	5.4	77	1,499,402	7.7	50	754,499	3.6	27	744,903
Testis	2.8	41	1,499,402	5.4	41	754,499	0.0	0	744,903
Thyroid	15.2	224	1,499,402	6.8	51	754,499	23.6	173	744,903
Pediatric Age 0 to 19	15.8	72	450,317	13.3	31	230,303	18.5	41	220,014

Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard.

2007 Idaho Cancer Incidence Counts by Behavior (Preliminary)

Primary Site	In situ	Malignant
All Sites	612	6,616
Bladder	165	131
Brain	0	99
Breast	175	958
Cervix	0	35
Colorectal	16	588
Corpus Uteri	1	180
Esophagus	0	69
Hodgkin Lymphoma	0	38
Kidney and Renal Pelvis	5	208
Larynx	2	43
Leukemia	0	205
Liver and Bile Duct	0	57
Lung and Bronchus	2	809
Melanoma of the Skin	195	334
Myeloma	0	82
Non-Hodgkin Lymphoma	0	297
Oral Cavity and Pharynx	1	164
Ovary	0	116
Pancreas	1	168
Prostate	3	1,150
Stomach	1	77
Testis	0	41
Thyroid	0	224
Pediatric Age 0 to 19	0	72

2007 Idaho Cancer Incidence Counts by SEER Summary Stage (Preliminary)

Primary Site	In situ	Localized	Regional	Distant	Unstaged
All Sites	612	2,991	1,245	1,529	851
Bladder	165	80	22	11	18
Brain	0	68	10	1	20
Breast	175	573	293	55	37
Cervix	0	16	8	10	1
Colorectal	16	213	205	110	60
Corpus Uteri	1	130	29	12	9
Esophagus	0	11	22	22	14
Hodgkin Lymphoma	0	4	18	12	4
Kidney and Renal Pelvis	5	125	32	28	23
Larynx	2	23	8	7	5
Leukemia	0	1	0	178	26
Liver and Bile Duct	0	15	17	5	20
Lung and Bronchus	2	110	135	442	122
Melanoma of the Skin	195	278	22	17	17
Myeloma	0	2	0	70	10
Non-Hodgkin Lymphoma	0	66	40	148	43
Oral Cavity and Pharynx	1	64	59	22	19
Ovary	0	11	20	72	13
Pancreas	1	12	46	68	42
Prostate	3	867	106	36	141
Stomach	1	19	15	25	18
Testis	0	26	9	5	1
Thyroid	0	158	55	6	5
Pediatric Age 0 to 19	0	24	12	30	6

2007 Idaho Cancer Incidence Rates by Age (Preliminary)

Age at Diagnosis	Rate	Cases	Pop
00-04	19.4	23	118,630
05-09	8.9	10	111,753
10-14	7.3	8	108,975
15-19	27.9	31	110,959
20-24	39.3	41	104,442
25-29	55.8	63	112,844
30-34	82.4	79	95,875
35-39	122.3	118	96,463
40-44	219.6	214	97,460
45-49	317.2	334	105,294
50-54	525.3	531	101,089
55-59	754.7	677	89,705
60-64	1,120.2	795	70,967
65-69	1,860.8	969	52,073
70-74	2,245.2	900	40,085
75-79	2,377.5	781	32,849
80-84	2,497.4	631	25,266
85+	2,334.5	576	24,673

Rates are per 100,000.

2007 Idaho Cancer Mortality Rates by Sex (Final)

Cause of Death	Total			Male			Female		
	Rate	Deaths	Pop	Rate	Deaths	Pop	Rate	Deaths	Pop
All Causes of Death	728.1	10,742	1,499,402	818.2	5,331	754,499	648.7	5,411	744,903
All Malignant Cancers	164.4	2,384	1,499,402	188.3	1,229	754,499	147.7	1,155	744,903
Bladder	4.7	68	1,499,402	7.7	48	754,499	2.4	20	744,903
Brain and Other Nervous System	5.0	72	1,499,402	4.1	30	754,499	5.8	42	744,903
Breast	11.5	168	1,499,402	0.0	0	754,499	21.4	168	744,903
Cervix	1.2	17	1,499,402	0.0	0	754,499	2.3	17	744,903
Colorectal	15.1	219	1,499,402	16.2	105	754,499	14.3	114	744,903
Corpus Uteri	1.4	20	1,499,402	0.0	0	754,499	2.6	20	744,903
Esophagus	4.3	63	1,499,402	7.4	50	754,499	1.7	13	744,903
Hodgkin Lymphoma	0.4	6	1,499,402	0.4	3	754,499	0.4	3	744,903
Kidney	3.8	57	1,499,402	4.6	32	754,499	3.1	25	744,903
Larynx	1.2	18	1,499,402	2.1	15	754,499	0.4	3	744,903
Leukemia	6.9	100	1,499,402	8.3	54	754,499	5.9	46	744,903
Liver and Bile Duct	3.6	52	1,499,402	3.9	26	754,499	3.5	26	744,903
Lung and Bronchus	41.2	595	1,499,402	50.9	332	754,499	33.8	263	744,903
Melanoma of the Skin	3.0	43	1,499,402	4.5	30	754,499	1.7	13	744,903
Myeloma	3.0	45	1,499,402	3.6	24	754,499	2.6	21	744,903
Non-Hodgkin Lymphoma	6.8	98	1,499,402	6.3	43	754,499	7.1	55	744,903
Oral Cavity and Pharynx	2.2	32	1,499,402	2.9	20	754,499	1.5	12	744,903
Ovary	5.0	73	1,499,402	0.0	0	754,499	9.3	73	744,903
Pancreas	10.4	152	1,499,402	12.2	83	754,499	8.8	69	744,903
Prostate	10.9	157	1,499,402	26.2	157	754,499	0.0	0	744,903
Stomach	3.2	45	1,499,402	4.9	31	754,499	1.8	14	744,903
Testis	0.0	0	1,499,402	0.0	0	754,499	0.0	0	744,903
Thyroid	0.4	6	1,499,402	0.5	3	754,499	0.4	3	744,903

Data source: Bureau of Vital Records and Health Statistics (BVRHS), Idaho Department of Health and Welfare, 2008.
 Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard.
 Cause of death categories are based on SEER cause of death recodes (<http://seer.cancer.gov/coderecode/>), which differ from official BVRHS cancer mortality categories.

REFERENCES

1. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S. *International Classification of Diseases for Oncology*. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
2. Young JL Jr., Roffers SD, Reis LAG, Fritz AG, Hurlbut AA (eds). *SEER Summary Staging Manual – 2000: Codes and Coding Instructions*. National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.
3. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds). *AJCC Cancer Staging Manual, Sixth Edition*. Chicago: American Joint Committee on Cancer; 2002.
4. Havener L, Hultstrom D (eds). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Tenth Edition, Version 11*. Springfield, IL: North American Association of Central Cancer Registries, November 2004.
5. Cunningham J, Hankey B, Lyles B, Percy C, Ries L, Seiffert J, Shambaugh E, Van Holten V (eds). *SEER Program Code Manual*, rev. ed., Cancer Statistics Branch, National Cancer Institute; 1992.
6. Phillips JL, Stewart A, Tary P (eds). *Facility Oncology Registry Data Standards (FORDS)*. Chicago, IL: American College of Surgeons, Commission on Cancer, 2004 revision.
7. National Center for Health Statistics. Estimates of the July 1, 2000-July 1, 2007, United States resident population from the Vintage 2007 postcensal series by year, county, age, sex, race, and Hispanic origin, prepared under a collaborative arrangement with the U.S. Census Bureau. Available on the Internet from: <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>. September 5, 2008.
8. Schottenfeld D, Fraumeni JF Jr. (eds). *Cancer Epidemiology and Prevention*. New York: Oxford University Press; 1996.
9. Lenhard RE, Osteen RT, Gansler T (eds). *Clinical Oncology*. The American Cancer Society, Inc.: Atlanta; 2001.
10. Report on Carcinogens, Eleventh Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program; 2005.
11. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (2000-2005) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.
12. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.3.0. Statistical Research and Applications Branch, National Cancer Institute, 2005. <http://srab.cancer.gov/devcan>.
13. Final 2007 mortality data, Bureau of Vital Records and Health Statistics, Idaho Department of Health and Welfare; November 2008.
14. Havener L (Ed). *Standards for Cancer Registries Volume III: Standards for Completeness, Quality, Analysis, and Management of Data*. Springfield (IL): North American Association of Central Cancer Registries, October 2004.
15. Johnson CJ, Carson SL. *Cancer in Idaho by Race and Ethnicity: 1990-2001*. Boise, ID: Cancer Data Registry of Idaho; October 2003. Available on the web at www.idcancer.org in the Special Reports section: <http://www.idcancer.org/special/Cancer%20in%20Idaho%20by%20Race%20and%20Ethnicity%201990%20to%202001.pdf>.
16. Collaborative Staging Task Force of the American Joint Committee on Cancer. *Collaborative Staging Manual and Coding Instructions, Version 1.04.00*. Jointly published by American Joint Committee on Cancer (Chicago, IL) and U.S. Department of Health and Human Services (Bethesda, MD), 2004. NIH Publication Number 04-5496.
17. Joinpoint Regression Program, Version 3.3.1. April 2008. Statistical Research and Applications Branch, National Cancer Institute. <http://srab.cancer.gov/joinpoint>.
18. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2004 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007. Available at: www.cdc.gov/uscs.
19. Furlow, B. *Accuracy of US cancer surveillance under threat*. The Lancet Oncology, Vol. 8 (Sep. 2007), pp. 762-763.
20. Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK. *The 2007 Multiple Primary and Histology Coding Rules*. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD, 2007.

APPENDIX A

STANDARD SITE ANALYSIS CATEGORIES

SITE CATEGORY	PRIMARY SITE CODE
Categories in SMALL CAPITALS are aggregated from groups indented under them	EXCLUDES histologic types 9590-9989
BUCCAL CAVITY & PHARYNX	
Lip	C00.0 - C00.9
Tongue	C01.9 - C02.9
Salivary Glands	C07.9 - C08.9
Floor of Mouth	C04.0 - C04.9
Gum and Other Mouth	C03.0 - C03.9 C05.0 - C05.9 C06.0 - C06.9
Nasopharynx	C11.0 - C11.9
Tonsil	C09.0 - C09.9
Oropharynx	C10.0 - C10.9
Hypopharynx	C12.9 C13.0 - C13.9
Other Buccal Cavity and Pharynx	C14.0 C14.2 - C14.8
DIGESTIVE SYSTEM	
Esophagus	C15.0 - C15.9
Stomach	C16.0 - C16.9
Small Intestine	C17.0 - C17.9
COLON (Excluding Rectum)	
Cecum	C18.0
Appendix	C18.1
Ascending Colon	C18.2
Hepatic Flexure	C18.3
Transverse Colon	C18.4
Splenic Flexure	C18.5
Descending Colon	C18.6
Sigmoid Colon	C18.7
Large Intestine, NOS	C18.8 – C18.9, C26.0

SITE CATEGORY Categories in SMALL CAPITALS are aggregated from the groups indented under them	PRIMARY SITE CODE EXCLUDES histologic types 9590-9989
RECTUM AND RECTOSIGMOID	
Rectosigmoid Junction	C19.9
Rectum	C20.9
Anus, Anal Canal, & Anorectum	C21.0 - C21.2 C21.8
Liver	C22.0
Intrahepatic Bile Duct	C22.1
Gallbladder	C23.9
Other Biliary	C24.0 - C24.9
Pancreas	C25.0 – C25.9
Retroperitoneum	C48.0
Peritoneum, Omentum, & Mesentery	C48.1 - C48.2
Other Digestive Organs	C26.8 – C26.9 C48.8
RESPIRATORY SYSTEM	
Nasal Cavity, Middle Ear, & Accessory Sinuses	C30.0 - C30.1 C31.0 - C31.9
Larynx	C32.0 - C32.9
Lung and Bronchus	C34.0 – C34.9
Pleura	C38.4
Trachea, Mediastinum, & Other Respiratory Organs	C33.9 C38.1 - C38.3 C38.8 C39.0 C39.8 C39.9
BONES AND JOINTS	C40.0 – C41.9
SOFT TISSUE (Including Heart)	C38.0 C47.0 – C47.9 C49.0 – C49.9

SITE CATEGORY	PRIMARY SITE CODE
Categories in SMALL CAPITALS are aggregated from the groups indented under them	EXCLUDES histologic types 9590-9989
SKIN (Excluding Basal and Squamous)	
Melanomas - Skin	C44.0 – C44.9 Histology Types 8720 - 8790 ONLY
Other Non - Epithelial	C44.0 – C44.9 Also Excluding Histology Types 8000 – 8004 8010 – 8045 8050 – 8082 8090 – 8110 8720 – 8790 9590 – 9989
BREAST	C50.0 – C50.9
FEMALE GENITAL SYSTEM	
Cervix Uteri	C53.0 – C53.9
Corpus Uteri	C54.0 – C54.9
Uterus, NOS	C55.9
Ovary	C56.9
Vagina	C52.9
Vulva	C51.0 – C51.9
Other Female Genital Organs	C57.0 – C58.9
MALE GENITAL SYSTEM	
Prostate	C61.9
Testis	C62.0 – C62.9
Penis	C60.0 – C60.9
Other Male Genital Organs	C63.0 – C63.9
URINARY SYSTEM	
Bladder	C67.0 – C67.9
Kidney and Renal Pelvis	C64.9 C65.9
Ureter	C66.9
Other Urinary Organs	C68.0 – C68.9
EYE AND ORBIT	C69.0 – C69.9

SITE CATEGORY Categories in SMALL CAPITALS are aggregated from the groups indented under them	PRIMARY SITE CODE EXCLUDES histologic types 9590-9989
BRAIN AND OTHER NERVOUS SYSTEM	
Brain	C71.0 – C71.9 Also excludes: 9530 - 9539 And 9590 – 9989
Other Nervous System	A) C71.0 – C71.9 (meningioma) Histologic Type: 9530- 9539 ONLY B) C70.0 - C70.9 C) C72.0 - C72.9
ENDOCRINE SYSTEM	
Thyroid	C73.9
Other Endocrine (Including Thymus)	C37.9 C74.0 - C74.9 C75.0 - C75.9

SITE CATEGORY	PRIMARY SITE CODE	HISTOLOGY
Categories in SMALL CAPITALS are aggregated from the groups indented under them		
LYMPHOMAS		
Hodgkin's Disease		
Nodal	C02.4, C09.8, C09.9, C11.1, C14.2, C37.9 C42.2 C77.0 - C77.9	Types: 9650 - 9667 ONLY
Extranodal	For All Other Sites Exclude Sites: C02.4, C09.8, C09.9, C11.1, C14.2, C37.9, C42.2 C77.0 - C77.9	Types: 9650 - 9667 ONLY
Non - Hodgkin's Disease		
Nodal	C02.4, C09.8, C09.9, C11.1, C14.2, C37.9, C42.2 C77.0 - C77.9	Types: 9590 - 9596 9670 - 9729, 9823, 9827 ONLY
Extranodal	For All Other Sites Excluding Sites: C02.4, C09.8, C09.9, C11.1, C14.2, C37.9, C42.2 C77.0 - C77.9	Types: 9590 - 9595 9670 - 9729 ONLY Types: 9823, 9827 For All Other Sites Except C42.0, C42.1, C42.4
MULTIPLE MYELOMA	For All Sites	Types: 9731 - 9732 ONLY

SITE CATEGORY	HISTOLOGY
Categories in SMALL CAPITALS are aggregated from the groups indented under them	
LEUKEMIAS	
Lymphocytic	
Acute Lymphocytic	Type: 9821, 9828, ONLY
Chronic Lymphocytic	Type: 9823 ONLY
Other Lymphocytic	Type: 9820, 9822, 9824, 9825, 9826, ONLY
Granulocytic (Myeloid)	
Acute Granulocytic	Type: 9840, 9861, 9866, 9867, 9871 - 9874 ONLY
Chronic Granulocytic	Type: 9863, 9868, ONLY
Other Granulocytic	Type: 9860, 9862, 9864, ONLY
Monocytic	
Acute Monocytic	Type: 9891 ONLY
Chronic Monocytic	Type: 9893 ONLY
Other Monocytic	Type: 9890, 9892, 9894, ONLY
Other	
Other Acute	Type: 9801, 9841, 9931, 9932 ONLY
Other Chronic	Type: 9803, 9842 ONLY
Aleukemic, Subleukemic, & NOS	Type: 9800, 9802, 9804, 9830, 9850, 9870, 9880, 9900, 9910, 9930, 9940, 9941 ONLY Type 9827 For Sites C42.0, C42.1, C42.4 ONLY

SITE CATEGORY	PRIMARY SITE CODE
Categories in SMALL CAPITALS are aggregated from the groups indented under them	EXCLUDES histologic types 9590-9989
ILL- DEFINED AND UNSPECIFIED SITES	A) Type: 9720 - 9723 9740 9741 9760 - 9764 9950 - 9989 ONLY For All Sites B) C76.0 - C76.8 C80.9 Type: 8000 - 9589 C) C42.0 - C42.4 Type 8000 - 9589 D) C77.0 - C77.9 Type 8000 - 9589
INVALID SITE	Site or histology code not within valid range or site code not found in this table.

Source: "Standards for Completeness, Quality, Analysis, and Management of Data, Vol III". North American Association of Central Cancer Registries, October 2004.¹⁴

APPENDIX B

2000 U.S. STANDARD POPULATION

Age Group	2000 US Standard Population (Census P25-1130)
0	3,794,901
1-4	15,191,619
5-9	19,919,840
10-14	20,056,779
15-19	19,819,518
20-24	18,257,225
25-29	17,722,067
30-34	19,511,370
35-39	22,179,956
40-44	22,479,229
45-49	19,805,793
50-54	17,224,359
55-59	13,307,234
60-64	10,654,272
65-69	9,409,940
70-74	8,725,574
75-79	7,414,559
80-84	4,900,234
85+	4,259,173
Total	274,633,642

Source: SEER Program, National Cancer Institute, 2008.¹¹

APPENDIX C

2007 POPULATION BY HEALTH DISTRICT, GENDER, AND AGE GROUP

	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	STATE
Males								
< 5	6,448	2,810	2,708	16,476	7,436	7,172	9,201	60,737
5 to 9	6,934	2,821	2,732	15,835	6,605	6,742	7,771	57,160
10 to 14	7,254	3,059	2,944	15,445	6,487	6,489	7,322	56,008
15 to 19	7,481	4,482	4,328	14,226	6,643	6,532	8,148	56,398
20 to 24	6,219	5,591	5,420	14,692	5,813	6,526	9,174	55,855
25 to 29	7,361	3,662	3,568	17,175	6,392	6,288	7,458	58,720
30 to 34	6,005	3,044	2,880	15,907	5,399	4,588	5,297	48,977
35 to 39	6,398	2,838	2,614	17,050	5,208	4,408	4,952	49,065
40 to 44	6,835	3,070	2,845	15,880	5,634	4,504	5,524	49,078
45 to 49	7,721	3,554	3,303	15,638	6,250	5,544	6,253	52,595
50 to 54	7,721	3,670	3,489	14,449	6,052	5,546	5,972	50,321
55 to 59	7,587	3,466	3,254	12,356	5,131	4,829	5,124	44,664
60 to 64	5,938	2,828	2,665	9,438	4,260	3,664	4,137	35,330
65 to 69	4,594	2,199	2,019	6,274	3,222	2,662	2,969	25,802
70 to 74	3,540	1,743	1,613	4,408	2,514	2,056	2,072	19,369
75 to 79	2,645	1,419	1,345	3,332	1,934	1,627	1,624	14,888
80 to 84	1,754	1,034	942	2,317	1,465	1,166	1,086	10,559
85+	1,434	960	920	1,835	1,377	854	868	8,973
Total	103,869	52,250	49,589	212,733	87,822	81,197	94,952	754,499
Females								
< 5	6,115	2,733	2,663	15,546	6,927	7,017	8,939	57,893
5 to 9	6,721	2,736	2,660	15,335	6,358	6,338	7,221	54,593
10 to 14	6,888	2,767	2,649	14,594	6,186	6,188	6,902	52,967
15 to 19	6,758	4,042	3,914	13,185	6,245	6,437	9,715	54,561
20 to 24	5,826	4,569	4,488	12,508	5,183	6,369	6,993	48,587
25 to 29	7,063	2,661	2,650	15,770	5,071	5,541	7,721	54,124
30 to 34	5,904	2,820	2,746	14,664	5,019	4,755	5,240	46,898
35 to 39	6,678	2,747	2,635	15,000	5,070	4,730	5,135	47,398
40 to 44	6,887	3,069	2,912	15,071	5,641	4,852	5,518	48,382
45 to 49	7,980	3,760	3,565	15,520	6,063	5,568	6,272	52,699
50 to 54	8,356	3,541	3,406	14,461	5,980	5,440	5,906	50,768
55 to 59	7,609	3,400	3,208	12,330	5,365	4,815	5,078	45,041
60 to 64	6,018	2,753	2,615	9,364	4,349	3,669	4,107	35,637
65 to 69	4,479	2,214	2,051	6,525	3,280	2,722	2,961	26,271
70 to 74	3,512	1,764	1,641	4,995	2,739	2,227	2,127	20,716
75 to 79	2,972	1,630	1,533	4,148	2,473	1,855	1,970	17,961
80 to 84	2,472	1,387	1,312	3,411	2,030	1,485	1,512	14,707
85+	2,338	1,545	1,466	3,618	2,256	1,675	1,429	15,700
Total	104,576	50,138	48,114	206,045	86,235	81,683	94,746	744,903
Total	208,445	102,388	97,703	418,778	174,057	162,880	189,698	1,499,402